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Pancreatic hormone secretionAlternative processing of the precursor protein pro-GIP results in endogenously produced GIP(1–30)NH2,
that by DPP-4 cleavage in vivo results in the metabolite GIP(3–30)NH2. We showed previously that GIP(3–
30)NH2 is a high affinity antagonist of the human GIPR in vitro. Here we determine whether it is suitable
for studies of GIP physiology in rats since effects of GIP agonists and antagonists are strictly species-
dependent. Transiently transfected COS-7 cells were assessed for cAMP accumulation upon ligand stim-
ulation or assayed in competition binding using human 125I-GIP(1–42) as radioligand. In isolated per-
fused rat pancreata, insulin, glucagon, and somatostatin-releasing properties were evaluated.
Competition binding demonstrated that on the rat GIP receptor (GIPR), rat GIP(3–30)NH2 bound with
high affinity (Ki of 17 nM), in contrast to human GIP(3–30)NH2 (Ki of 250 nM). In cAMP studies, rat GIP
(3–30)NH2 inhibited GIP(1–42)-induced rat GIPR activation and schild-plot analysis showed competitive
antagonism with a pA2 of 13 nM and a slope of 0.9 ± 0.09. Alone, rat GIP(3–30)NH2 displayed weak, low-
potent partial agonistic properties (EC50 > 1 mM) with an efficacy of 9.4% at 0.32 mM compared to GIP(1–
42). In perfused rat pancreata, rat GIP(3–30)NH2 efficiently antagonized rat GIP(1–42)-induced insulin,
somatostatin, and glucagon secretion. In summary, rat GIP(3–30)NH2 is a high affinity competitive
GIPR antagonist and effectively antagonizes GIP-mediated G protein-signaling as well as pancreatic hor-
mone release, while human GIP(3–30)NH2, despite a difference of only one amino acid between the two
(arginine in position 18 in rat GIP(3–30)NH2; histidine in human), is unsuitable in the rat system. This
underlines the importance of species differences in the GIP system, and the limitations of testing human
peptides in rodent systems.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
GIP(1–42) is known as a postprandial gut hormone secreted
from enteroendocrine K cells of the small intestine [1] together
with other gut hormones [2,3]. Following a meal, GIP(1–42) enters
the circulation and potentiates glucose-mediated insulin secretionfrom the pancreas [4]. Additional pancreatic effects may include
stimulation of glucagon secretion from the a-cells [5,6] and
somatostatin release from d-cells [7,8]. The GIP receptor (GIPR) is
widely expressed in various tissues besides the pancreas including
adipose, bone, and lung tissue [9,10]. Particularly, the relationship
between adipose tissue biology and the GIP system has received
much interest. GIPR knock out mice are resistant to diet-induced
obesity and crossing this mouse with the leptin mutant (ob/ob)
mouse, which is an established mouse model for hyperphagic obe-
sity, reduced weight gain by 23% [11], whereas transgenic GIPR
expression in adipose tissue in global GIPR knock out mice restores
diet-induced body weight gain [12]. Moreover, a recent study
showed that heterogeneous abrogation of the GIP gene displays
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lin resistance and weight gain when compared to wild type and
homogenous abrogation [13]. If GIP’s physiology in rodents is mir-
rored in humans, these results support the use of GIPR antagonists
as potential therapeutics for the treatment of obesity.
Various strategies have been pursued in the search for GIPR
antagonists. Antibodies raised against both GIP(1–42) [14,15] or
the GIPR [16,17], a small molecule antagonist [18], amino acid sub-
stitutions of GIP(1–42) [19], and various GIP(1–42) truncations and
modifications such as e.g. Pro3(GIP) [20–24] have all been reported
to be effective, but none have been found suitable for human stud-
ies. In 2006, we showed that the dipeptidyl peptidase-4 (DPP-4)-
mediated metabolite, porcine GIP(3–42), antagonized porcine GIP
(1–42)-mediated cAMP accumulation, but had no antagonistic
effects in anesthetized pigs at physiological concentrations [22].
Recently, an alternative processing of the precursor protein pro-
GIP was shown to occur in the a-cells of the pancreas and in a sub-
set of the K-cells of the small intestine, which potentially leads to
the secretion of GIP(1–30)NH2 [25,26]. We combined the previ-
ously reported N-terminal truncation GIP(3–42) with this C-
terminally truncated GIP(1–30)NH2 to design the GIP(3–30)NH2
(which is a naturally occurring metabolite of the DPP-4 cleaved
GIP(1–30)NH2), and demonstrated that GIP(3–30)NH2 is an effec-
tive competitive antagonist on the human GIPR [27]. In fact, it
was superior to other truncations of the N-terminus (GIP(2-, 4-,
5-, 6-, 7-, 8-, and 9–30)NH2) and to GIP(3–42) in terms of basic
binding affinity and antagonistic properties of the human GIPR
in vitro. In the present study, we determine whether GIP(3–30)
NH2 is sufficiently active in the rat model system to be used for
studies elucidating the role of GIP in physiology and
pathophysiology.2. Materials and methods
2.1. Materials
Rat GIP(1–42) (cat. No. 027-12) was purchased from Phoenix
Pharmaceuticals, Karlsruhe, Germany. Human GIP(1–42) (H5645)
was purchased from Bachem, Bubendorf, Switzerland. Human
and rat GIP(3–30)NH2 and GIP(1–30)NH2 were synthesized by
CASLO ApS, Lyngby, Denmark. All peptides had a purity of more
than 95% by HPLC analysis and had the correct mass spectrometry
controlled molecular weight. cDNAs of the human and rat GIPR
were purchased from Origene, Rockville, Maryland, USA
(SC110906, RN212314, and MC216211, respectively) and cloned
into the pCMV-Script vector. Human 125I-labeled GIP(1–42) and
125I-labeled Tyr11-somatostatin were purchased from PerkinElmer
Life Sciences, Skovlunde, Denmark (NEX402 and NEX389, respec-
tively). 125I-labeled glucagon and human 125I-insulin were kind
gifts from Novo Nordisk A/S.2.2. Animals
All animal care and experimental procedures were complied
with institutional guidelines and approved by the Danish Animal
Experiments Inspectorate (2013-15-2934-00833). Studies involv-
ing animals are reported in accordance with the ARRIVE guidelines
for reporting experiments involving animals [28].
Male Wistar rats (220–250 g) were purchased from Janvier, Le
Genest-Saint-Isle, France. The animals were housed in plastic-
bottomed wire-lidded cages in air-conditioned (21 C) and humid-
ity controlled (55%) rooms with a 12:12 h light-dark cycle and free
access to standard rat chow and water. Animals were acclimatised
for at least one week before use.2.3. Transfections and tissue culture
COS-7 cells were cultured at 10% CO2 and 37 C in Dulbecco’s
modified Eagle’s medium 1885 supplemented with 10% foetal
bovine serum, 2 mM glutamine, 180 units/ml penicillin, and 45 g/
ml streptomycin. Transient transfection of the COS-7 cells for
cAMP accumulation and competition binding was performed using
the calcium phosphate precipitation method with the addition of
chloroquine [29].2.4. cAMP assay
Transiently transfected COS-7 cells were seeded in white 96-
well plates at a density of 3 * 104cells/well. One day after, the cells
were washed twice with Hepes-buffered saline (HBS) buffer and
incubated with HBS and 1 mM 3-isobutyl-1-methylxanthine
(IBMX) for 30 min at 37 C. To test agonists, ligands were added
and incubated for 30 min at 37 C. In order to test for antagonistic
properties, the cells were preincubated for 10 min with the antag-
onist with subsequent addition of the agonist and incubated for a
further 20 min. The HitHunterTM cAMP XS assay (DiscoveRx, Herlev,
Denmark) was carried out according to the manufacturer’s
instructions.2.5. Competition binding assay
COS-7 cells were seeded in clear 96-well plates the day after
transient transfection. The number of cells added per well was gov-
erned by the apparent expression efficiency of the receptor, aiming
for 5–10% specific binding of the radioactive ligand. The following
day, cells were assayed by competition binding for 4 h at 4 C using
15–40 pM of 125I-labeled GIP(1–42) as well as unlabeled ligand in a
total volume of 100 ll per well in 50 mM Hepes buffer (pH 7.2)
supplemented with 0.5% bovine serum albumin (BSA) (binding-
buffer). After incubation, the cells were washed twice in 100 ll
per well ice-cold binding buffer and lysed using 175 ll per well
of 200 mM NaOH with 1% SDS for 30 min. Nonspecific binding
was determined as the binding in the presence of 100 nM unla-
beled ligand. The samples were analysed by the Wallac Wizard
1470 Gamma Counter.2.6. Isolated perfused rat pancreas
Male Wistar rats (220–250 g) were anaesthetized (0.0158 mg
fentanyl citrat + 0.5 mg fluanisone + 0.25 mg midazolam/100 g;
Pharmacy Service, Denmark) and the pancreas was dissected and
perfused in situ as described previously [22]. Briefly, the pancreas
was perfused in a single-pass system through both the coeliac
and the superior mesenteric artery via a catheter inserted into
the aorta. All other aortic branches were ligated. The venous efflu-
ent was collected for 1 min intervals via a catheter in the portal
vein, and stored at 20 C until analysis. The pancreas was per-
fused with a modified Krebs Ringer bicarbonate buffer containing
in addition of 5% dextran (Pharmacosmos, Holbaek, Denmark),
0.1% BSA, fumarate, glutamate, and pyruvate (5 mM of each), and
7 mM glucose. Flow rate was kept constant at 4 ml/min, perfusion
buffer was heated and oxygenated (95% O2, 5% CO2), and pressure
was continuously measured throughout the experiment. Rat GIP
(3–30)NH2 and rat GIP(1–42) were infused as test substances
through a sidearm infusion pump at a flow rate of 0.2 ml/min. Argi-
nine (10 mM) was infused at the end of each experiment as a pos-
itive control.
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Hormone concentrations in the perfusion effluent were mea-
sured using in-house radioimmunoassays. Glucagon was measured
using a side viewing antiserum (code no 4304) recognizing a mid
sequence of glucagon, using synthetic glucagon for standards and
125I-labeled glucagon as tracer [30]. Insulin was measured using
an antibody cross-reacting strongly with rat insulin I and II (code
no. 2006-3). As standard we used human insulin and the tracer
was 125I-labeled human insulin [31]. Somatostatin concentrations
were determined using a rabbit antiserum (code no. 1758) raised
against synthetic cyclic somatostatin, recognizing both somato-
statin 14 and -28 [32], somatostatin 14 as standard and
125I-labeled Tyr11-somatostatin as tracer.
2.8. Data- and statistical analysis
IC50, EC50, and Ki values were determined by nonlinear regres-
sion using GraphPad Prism 7 (San Diego, California, United States
of America). Sigmoid curves were fitted logistically with a Hillslope
of 1.0 for the activation curves and -1.0 for the inhibition of cAMP
and binding. Ki values were calculated using the Cheng-Prusoff for-
mula under the assumption of one class of binding sites. Dose
ratios (DR) for the Schild analyses were based on the potency shift
of rat GIP(1–42) in the presence of a given rat GIP(3–30)NH2 con-
centration, relative to the absence of GIP(3–30)NH2. Schild plots
were performed with log(DR-1) (ordinate) and log(antagonist con-
centration) (abscissa) to estimate the slopes and Ki values. For the
rat pancreas perfusion data, baseline subtracted hormone output
responses were evaluated using one-way ANOVA for repeated
measurements. All calculations were performed using the software
GraphPad Prism 7 with p-values <0.05 being considered signifi-
cantly different.
2.9. Sequence alignments
The amino acid sequences of the rat/human GIP were acquired
from GenBank of NCBI. The alignment was done in Geneious 6.0.5
using MAFFT v6.814b. The BLOSUM62matrix was applied with gap
open penalty and offset value of 1.53 and 0.123, respectively. The
sequence logo was generated using the web-based program
WebLogo (http://weblogo.berkeley.edu) and the various mam-
malian GIP sequences were acquired from ensembl.org and uni-
prot.org.3. Results
3.1. Human GIP(3–30)NH2 displays a surprisingly low affinity on the
rat GIPR compared to rat GIP(3–30)NH2
In order to determine whether the double truncation of
GIP(1–42), which leads to GIP(3–30)NH2, is an effective antagonist
in vivo using the rat as a model system, we initially evaluated the
affinity of the ligand in vitro. Competition binding was conducted
on transiently transfected COS-7 cells expressing the rat GIPR
with 125I-labeled GIP(1–42) as the radioligand. GIP(1–30)NH2
was included to enable assessment of the significance of the
C-terminus in terms of GIPR binding. In light of our recent study
identifying major interspecies differences between rodents
and humans within the GIP system [24], both rat and human
GIP(1–42), GIP(1–30)NH2, and GIP(3–30)NH2 were included.
Human and rat GIP(1–42) were found to bind to the rat GIPR with
equally high affinities (Ki of 1.1 nM for human GIP(1–42) and Ki of
0.88 nM for rat GIP(1–42)) (Fig. 1A). In contrast, rat GIP(1–30)NH2
displayed a statistically significant improved affinity compared tohuman GIP(1–30)NH2 with Ki of 0.4 and 1.5, respectively
(Fig. 1B). This species difference became even more pronounced
for GIP(3–30)NH2 which showed a 15-fold shift in affinity. For rat
GIP(3–30)NH2, the Ki was 17 nM, which is a 19-fold reduction
compared to rat GIP(1–42). In contrast, human GIP(3–30)NH2
had a Ki of 250 nM and thus a 227-fold lower affinity for the rat
GIPR compared to human GIP(1–42). When looking at the
sequence differences between species (Fig. 1D), only one amino
acid (position 18 with arginine in rat and histidine in human
GIP) differs between rat and human GIP(1–30)NH2/GIP(3–30)
NH2. In fact, among the 42 sequences of GIP identified so far, a his-
tidine is found at this position in all human and non-human pri-
mates (10 sequences), whereas GIP in the remaining 32 species
has an arginine (Fig. 2A, B). Importantly, this alteration of position
18 had a large effect on the binding properties of GIP(3–30)NH2, a
minor effect on GIP(1–30)NH2 binding, whereas it did not affect
the binding affinity of GIP(1–42).
3.2. GIP(3–30)NH2 is an antagonist of the rat GIPR
To investigate whether the high affinity of GIP(3–30)NH2
reflects high antagonistic potency, as observed in the human GIP
system [27], we chose the GIPR-induced cAMP accumulation, a
well-established signaling pathway for GIPR activation [33,34], in
transiently transfected COS-7 cells. GIP(1–42) and GIP(1–30)NH2
were included to examine whether both forms activate the rat
GIPR in a similar manner. For GIP(3–30)NH2, the evaluation was
conducted both in the absence and presence of rat or human GIP
(1–42) in amounts corresponding to 60% Emax. As previously
shown [24], rat GIP(1–42) was more potent and efficacious on
the rat GIPR compared to human GIP(1–42) with EC50 values of
11 and 58 pM and Emax values of 100 and 76%, respectively
(Fig. 3A). In contrast, rat and human GIP(1–30)NH2 were more sim-
ilar to EC50 values of 18 and 38 pM and Emax values of 92 and 87%,
respectively (Fig. 3B). Due to the higher potency and efficacy of rat
GIP(1–42) compared to human GIP(1–42), 10 pM and 316 pMwere
chosen to achieve 60% of Emax for the evaluation of GIP(3–30)NH2
antagonism of rat and human GIP(1–42), respectively. In the
absence of GIP(1–42), rat GIP(3–30)NH2 displayed a low-potent
partial agonistic profile with an efficacy of 9.4% at 0.32 mM
(Fig. 3C), while no agonistic properties were observed for human
GIP(3–30)NH2 even at the highest concentration (0.32 mM). In the
presence of rat GIP(1–42), rat GIP(3–30)NH2 antagonized rat
GIPR-induced cAMP accumulation dose-dependently with an esti-
mated EC50-value of 118 nM. A similar pattern was observed for
human GIP(3–30)NH2 which dose-dependently inhibited human
GIP(1–42), however, with an estimated EC50-value of 380 nM
(Fig. 3D). Thus, rat GIP(3–30)NH2 is more potent as an antagonist
on the rat GIPR than human GIP(3–30)NH2, a pattern that mim-
icked the low affinity obtained for human GIP(3–30)NH2 as com-
pared to the rat counterpart (Fig. 1C), and rat GIP(3–30)NH2 was
therefore chosen for further investigation.
3.3. Rat GIP(3–30)NH2 is a high affinity competitive antagonist of the
rat GIPR
To determine the nature of the antagonistic properties of rat GIP
(3–30)NH2 on the rat GIPR, cAMP accumulation was measured as a
function of increasing concentrations of rat GIP(1–42) in the
absence or presence of fixed concentrations of rat GIP(3–30)NH2
(Fig. 4A). Rightward shifts in potency of rat GIP(1–42) were
observed with increased rat GIP(3–30)NH2 concentration which
is in line with the antagonistic properties (Fig. 3C). At concentra-
tions from 17.8 to 316 nM of rat GIP(3–30)NH2, the potency
(EC50) of rat GIP(1–42) decreased 2.6 to 28-fold compared to in
the absence of rat GIP(3–30)NH2. Based on these EC50 values for
Fig. 1. Rat GIP(3–30)NH2 binds to the rat GIPR with high affinity. The binding of 125I-labeled human GIP(1–42) to the transiently transfected COS-7 cells with rat GIPR cDNA,
was tested in the presence of increasing amounts of (A) rat GIP(1–42) (▲), human GIP(1–42) (s), (B) rat GIP(1–30)NH2 (▲), human GIP(1–30)NH2 (s), (C) rat GIP(3–30)NH2
(▲) or human GIP(3–30)NH2 (s). The data were normalized to maximal specific binding and shown as mean ± SEM, n  3 independent experiments carried out in duplicates.
Nonlinear regression was used to calculate the IC50 value. (D) Structure overview with nonconserved residues highlighted of full length GIP(1–42) and GIP(3–30)NH2 for both
human and rat GIP(3–30)NH2. The N-terminus not involved in binding to extracellular receptor domains is emphasized with a darker grey and position 18 is highlighted in
the peptide model.
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analysis determines whether an antagonist acts competitively; if
so, the equilibrium inhibitory constant (Ki) can be determined from
the X-axis intercept (pA2). A straight line relating the potency shifts
with a Hill slope of 1.0 indicates competitive antagonism and the
X-intercept or pA2-value of the Schild plot corresponds to the Ki
of the antagonist. The Hill coefficient was 0.9 ± 0.09 which proves
the competitive nature of rat GIP(3–30)NH2 and the pA2-value
was 13 nM. This corresponds well with the Ki of 17 nM for rat
GIP(3–30)NH2 observed from the competition binding (Fig. 1C),
and thereby confirms the high affinity binding of GIP(3–30)NH2
to the GIP receptor.3.4. Rat GIP(3–30)NH2 inhibits GIP(1–42)-induced hormone secretion
from the perfused pancreas
To determine whether the antagonistic properties from the
cAMP measurements reflected a physiological antagonism of GIP-
mediated pancreatic output, we used isolated perfused rat pancre-
ata. In this model, rat GIP(1–42) and rat GIP(3–30)NH2 were added
to the arterial perfusate. The venous effluent was collected at 1 min
intervals and the pancreatic output in terms of insulin, glucagon,
and somatostatin was determined. To ensure detection of possible
antagonistic properties of rat GIP(3–30)NH2, a rat GIP(1–42) con-
centration, which still elicited a prominent release of each of the
three pancreatic hormones of interest, was determined in the per-
fusion model. Three different concentrations of rat GIP(1–42) were
tested (10 pM, 100 pM and 1 nM). From these experiments, 1 nM
rat GIP(1–42) was chosen due to a significant release of all three
hormones at this concentration (data not shown). 1 mM rat GIP
(3–30)NH2 was applied to ensure adequate antagonism. A preincu-
bation with rat GIP(3–30)NH2 and subsequent co-perfusion with
both rat GIP(3–30)NH2 and rat GIP(1–42) resulted in a clear, effec-
tive reduction in both the insulin, glucagon, and somatostatin out-
put from the rat pancreata. Rat GIP(3–30)NH2 demonstrated clear
antagonism on the pancreatic b-, d-, and a-cells, respectively
(Fig. 5A–C). The same hormone release pattern was observed when
the stimulation order was switched giving the mono-perfusion of
rat GIP(1–42) before the co-perfusion with rat GIP(3–30)NH2 and
rat GIP(1–42) (data not shown). Furthermore, the partial agonismof rat GIP(3–30)NH2 observed in vitro (Fig. 3C) was not reproduced
for any of the hormonal responses during the single perfusion with
rat GIP(3–30)NH2 (Fig. 5A–C). Thus, a significant GIPR antagonism
by GIP(3–30)NH2 on pancreatic insulin, glucagon, and somato-
statin secretion was confirmed (Fig. 5A–C, total output shown as
columns).
4. Discussion
Our study demonstrates that rat GIP(3–30)NH2 is a high affinity
competitive antagonist on the rat GIPR in vitro and in the surviving
perfused rat pancreas, whereas human GIP(3–30)NH2 displays
much lower affinity and a consequent lower antagonistic potency
on the rat GIPR. This indicates that human GIP(3–30)NH2 is irrele-
vant in the rat GIP system, whereas rat GIP(3–30)NH2 can be used
as a tool to study the GIP physiology when using the rat as a model
system. To substantiate this, we show that rat GIP(3–30)NH2 inhi-
bits GIP(1–42)-mediated hormone release from the intact pancreas
as evident from the strong inhibition of GIP(1–42)-mediated insu-
lin, glucagon, and somatostatin release from b-, a-, and d-cells of
the pancreas (Fig. 5). This establishes GIP(3–30)NH2 as an effective
antagonist in a physiological system.
4.1. The C-terminal truncation improves antagonistic properties of GIP
(3–30)NH2 versus GIP(3–42), but not agonism of GIP(1–30)NH2 versus
GIP(1–42)
The function of the 12 amino acids of the C-terminus of GIP(1–
42) remains elusive. We previously showed that human GIP(3–30)
NH2 inhibited the human GIPR more potently compared to human
GIP(3–42) [27]. Moreover, a recent study reported that palmitoy-
lated human GIP(3–30)NH2Cex (where Cex is a C-terminal exten-
sion of exendin) was able to antagonize GIP(1–42)-mediated
insulin release in vitro from a rat b-cell line (BRIN-BD11 cells)
[35]. However, when comparing the corresponding agonists (GIP
(1–42) and GIP(1–30)NH2) the differences are indistinguishable
in terms of cAMP accumulation [27,36–38]. From a physiological
perspective, both molecular forms have been shown to stimulate
insulin secretion [26,39] and b-cell survival equipotently [40];
however, GIP(1–30)NH2 has a reduced effect on lipoprotein lipase
Fig. 2. Conservation of GIP(1–42) among mammals. (A) 41 of the available mammal sequences of the GIP(1–42) protein from ensembl.org and uniprot.org aligned with
mismatches from the human sequence highlighted in black. Especially the C-terminus and position 18 of GIP(1–42) is less conserved. (B) The degree of conservation of the GIP
(1–42) protein sequence between available mammal sequences displayed as sequence logo. The amino acids in black are fully conserved.
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tion in rats [41]. In addition, a controversy exists in terms of gastric
somatostatin release as GIP(1–30)NH2 has been shown to be
equipotent in mice [25] and less potent in rats [42], compared toGIP(1–42). In structure-activity studies, all the pivotal amino acids
involved in the GIPR interaction are found within the first 30
amino acids [38,43], with the C-terminal part initiating binding
with the extracellular receptor domains (ECD) while the N-
Fig. 3. Human and rat GIP(3–30)NH2 are antagonists of the rat GIPR. COS-7 cells
were transiently transfected with rat GIPR cDNA and assayed for cAMP accumu-
lation following stimulation of (A) human GIP(1–42) (s) or rat GIP(1–42) (▲), (B)
human GIP(1–30)NH2 (s) or rat GIP(1–30)NH2 (▲), (C) increasing concentrations of
rat GIP(3–30)NH2 in the absence (4) and presence of 10 pM rat GIP(1–42) (▲), and
(D) increasing concentrations of human GIP(3–30)NH2 in the absence (s) and
presence of 316 pM human GIP(1–42) (d). The data were normalized to Emax of rat
GIP(1–42) (A, B, C) or Emax of human GIP(1–42) (D) and shown as mean ± SEM, n  3
independent experiments carried out in duplicates. Nonlinear regression was used
to calculate the IC50 value.
Fig. 4. Rat GIP(3–30)NH2 is a high affinity competitive antagonist of the rat GIPR.
(A) Rat GIP(1–42) cAMP accumulation dose–response curves in the absence of and
with increasing concentrations of rat GIP(3–30)NH2: 0 nM (s), 17.8 nM (*), 31.6 nM
(.), 56.2 nM (r), 100 nM (d), 178 nM (j), and 316 nM (N) are displayed. The data
were normalized to Emax of each curve and shown as mean ± SEM, n = 3 indepen-
dent experiments carried out in duplicates. Nonlinear regression was used to
calculate EC50 values. (B) The corresponding Schild plot of the dose-response curves
revealed a pA2/Ki-value of 13 nM.
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receptor segments [43,44]. Particularly important GIP(1–42) resi-
dues involved in the binding to the ECD include Phe22, Val23,
Leu26, and Leu27 which participate in hydrophobic interactions
with ECD and the hydrophilic Asp15, Gln19, and Gln20 which
interact with the ECD through hydrogen bonds [43]. In support
of this, the truncations GIP(15–30)NH2 and GIP(15–30) still retain
binding, albeit with a 400-fold reduction compared to GIP(1–42)
[38]. Following binding of GIP(1–42)’s C-terminal to the ECD, Tyr1
appears to interact with multiple amino acids of the transmem-
brane receptor segments of the GIPR [45,46] and is pivotal for
receptor activation [47], which is in line with the inactivation ofGIP by DPP-4 and with the present study showing GIP(3–30)NH2
as an effective antagonist [22,48]. Furthermore, alanine screening
of the N-terminus of human GIP(1–42) has identified Glu3, Gly4,
Thr5, and Ile7 as highly important for GIP(1–42)-induced insulin
secretion in a rat cell line [47]. This so-called two step receptor acti-
vation not only describes GIPR activation, but is thought as a gen-
eral activation mechanism for secretin-like receptors [44,49–52],
and even for receptors outside the secretin-like receptors, such as
the chemokine receptors, which belong to the class of rhodopsin-
like receptors [44,53]. Moreover, when determining the degree of
conservation of GIP between mammalian species, most of the vari-
ation is found among residues 30– 42 (Fig. 2B). In the present
study, we found that human and rat GIP(1–42) bound with equal
affinity to the rat GIPR, and only minor differences between human
and rat GIP(1–30)NH2 were observed. As previously shown, rat GIP
(1–42) had greater agonistic potency and efficacy with respect to
cAMP accumulation compared to human GIP(1–42) on the rat GIPR
[24]. Surprisingly, a similar species difference was not observed
between human and rat GIP(1–30)NH2 indicating that the activity
via Gas is independent of whether an arginine (rat) or a histidine
(human) is found in position 18. When looking at the rat ligands
only, GIP(1–42) and GIP(1–30)NH2 activated the rat GIPR in a com-
pletely identical manner confirming that the C-terminus does not
have an impact on the agonistic properties. This is in agreement
with previous work showing that human GIP(1–42) and GIP(1–
30)NH2 activate the human GIPR in an identical manner [27].
4.2. Position 18 impacts the antagonistic potential of GIP(3–30)NH2 on
the rat GIPR
In contrast to the single C-terminally truncated GIP(1–30)NH2,
the double truncated GIP(3–30)NH2 showed species-dependent
variation as the rat GIP(3–30)NH2 displayed both higher affinity
and antagonistic potency of GIP-induced cAMP accumulation for
the rat GIPR compared to human GIP(3–30)NH2. Since position
18 is the only difference between human and rat GIP(1–30)NH2/
GIP(3–30)NH2, the N-terminal truncation very likely exposes posi-
tion 18 differently to the extracellular GIPR binding domain and
thereby explains the shift in affinity. When taking a closer look
at the GIP sequence among 41 species, most variations are
observed in the C-terminal region (Fig. 2) and in comparison to
the other incretin hormone, Glucagon-Like Peptide-1 (GLP-1), GIP
is much less conserved between species [54]. However, position
18 remains conserved showing only a conservative substitution
between histidine (in primates) and arginine (in rodents) - provid-
ing stronger antagonism with an arginine at this position. Confirm-
ing this, we observed a better antagonistic potency with porcine
GIP(3–42), (arginine at position 18) compared to human GIP(3–
42) (histidine at position 18) on the human GIPR [27]. Thus despite
another variation in position 34 (serine vs. asparagine in pig vs.
human, respectively), it is likely that this will also apply for the
C-terminal truncated forms, such as GIP(3–30)NH2.
4.3. Caution should be exercised when testing human GIP analogues in
rodents
Researchers striving for the elucidation of human GIP physiol-
ogy have used rodent in vivo models extensively. Much attention
has been given to the presumed GIPR antagonist, (Pro3)GIP, in
rodent models [19,55–57], however, we recently discovered that
human (Pro3)GIP is a partial agonist on the rodent GIPRs but a full
agonist on the human GIPR [24]. Thus, interspecies differences at
both the receptor and ligand level are important to consider when
evaluating the potential of a new compound, a fact that has been
neglected in previous studies (Tables 1 and 2). In addition, there
are many differences related to the organ of interest between
Fig. 5. Antagonistic effects of rat GIP(3–30)NH2 on insulin, glucagon, and somatostatin secretion are observed in perfused rat pancreata. Insulin (A), glucagon (B), and
somatostatin (C) secretion following stimulation of perfused rat pancreata by either 1 nM rat GIP(1–42) and 1 lM rat GIP(3–30)NH2 with a 5 min preincubation of 1 lM rat
GIP(3–30)NH2, 1 nM rat GIP(1–42), 1 lM rat GIP(3–30)NH2 or 10 mM arginine, n = 6 independent experiments. The glucose concentration was 7 mM and data are
mean ± SEM. Baseline subtracted total outputs of insulin (A), glucagon (B), and somatostatin (C) during the 10 min infusion of rat GIP(1–42)/rat GIP(3–30)NH2 are compared
using a one-way ANOVA with multiple comparisons; mean ± S.E.M., ****P < 0.0001, **P < 0.01, and *P < 0.05.
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creas. This includes the topographical organization the rodent
islets with the b-cells concentrated in the core surrounded by a
mantle of a-cells and d-cells. In contrast, the different cells of the
human islet are highly dispersed [58–61], which may promote dif-
ferent potential paracrine effects and different intra-islet commu-
nication. On a structural level, our study emphasizes differences
between GIPR, GIP(1–42), and GIP(3–30)NH2 of rodent or human
sequences (Figs. 1 and 3) and establishes that application of the
DPP-4 metabolite of human GIP(1–30)NH2, human GIP(3–30)
NH2, in rodent models would be misleading. Thus, a characteriza-
tion of this antagonist and variants hereof should be carried out
in human studies. Importantly, such studies could lead to theestablishment of an effective tool for the elucidation of human
GIP physiology and putatively result in a novel therapeutic possi-
bility for the treatment of obesity. The rodent counterparts, on
the other hand, must be used to characterize the GIP system in
rodents.
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Table 1
Overview of truncated GIP variants tested on the rat GIPR. The table displays an overview of truncated GIP variants of various different species tested on the rat GIPR both in vitro
and in vivo. Percentages compared to full agonist GIP(1–42) or GIP(1–30) results. Results showing no binding, agonism or antagonism are in italic. GIP = species sequence of ligand,
B = bovine, P = porcine, Hu = human, US = unknown species, UC = unknown concentration.
Truncation GIP Rat GIPR




(3–30)NH2 R COS cells: cAMP, antagonism (EC50 120 nM), low partial
agonist, Emax 9.4% activity (0.32 lM) vs. GIP(1-42)
Pancreas perfusion: inhibition of GIP-mediated insulin,
glucagon, and somatostatin release
COS cells: IC50 17nM Figs. 1C, 3C, and 5
(6–30)NH2 P CHO cells: cAMP: 58% inhibition (0.1 lM) CHO cells: Equal IC50 to GIP(1-42) [20]
(7–30)NH2 P CHO cells: 25% cAMP inhibition (0.1 lM)
L293 cells: cAMP inhibition IC50 0.1 lM
In vivo: 100 nmol/kg abolishes 1.5 nmol/kg GIP-insulin
secretion and reduces meal-induced insulin with 55%.
CHO cells: IC50 24 nM
L293 cells: IC50 200 nM
[38,62]
P CHO cells: 10 lM decreases GIP(1-42) cAMP by 34%
3 lg/250 g: 30% inhibition of glucose-induced insulin,
15% plasma glucose, 54% meal-induced insulin. 20 lg/kg
reduced glucose-uptake 30%.
CHO cells: IC50 177 nM [63,20]
(10–30) P CHO cells: 50%-inhibition in cAMP (10 lM) CHO cells: 187 fold decreased IC50 [20]
(15–30)NH2 P CHO cells: cAMP, antagonism (10 lM): 30 % of GIP(7–30)
Pancreas perfusion: No insulin release (1 ng/ml)
CHO cells: IC50 1400 nM [38,64]
(16–30)NH2 P CHO cells: cAMP, antagonism(10 lM): 20 % of GIP(7–30)
L293 cells: No cAMP or GIP-inhib.(10 nM)
CHO cells: IC50 2530 nM [38,62]
(17–30)NH2 P CHO cells: cAMP, antagonism (10 lM): 30 % of GIP(7–30)
Pancreas perfusion: 38% insulin release (1 ng/ml)
CHO cells: IC50 1540 nM [38,64]
(19–30)NH2 P CHO cells: 40% cAMP production (20 lM)
Pancreas perfusion: 60% insulin release (1 ng/ml)
In vivo: Significant glucose decrease (100 pmol/min/
100g)
CHO cells: 52% binding (10 lM) [38,64]
P CHO cells: No cAMP (1 lM) CHO cells: No binding (1 lM) [65]




(3–42) US BRIN-BD11: 30% cAMP (EC50  nM) and 1 lM inhibits
45%. 70% inhibition of insulin release by 1 lM
[23]
P Pan. perfusion: Inhibition of insulin, IC50 138nM [66]
(4–42) US BRIN-BD11: 50% cAMP, 30% inhibition of insulin (1 lM) [23]
(5–42) US BRIN-BD11: 35% cAMP (1 lM), insulin inhibition 70%
(6–42) US BRIN-BD11: 80% cAMP (1 lM), insulin inhibition 40%
(7–42) US BRIN-BD11: 65% cAMP (1 lM), insulin inhibition 55%
(8–42) US RINm5F: 30-fold decrease of GIP(1–42) potency (5 lM) [67]
US BRIN-BD11: 16% cAMP (1 lM), insulin inhibition 65% [23]
(9–42) US BRIN-BD11: 100% cAMP (1 lM), 100% insulin secretion
(15–42) P CHO cells: cAMP, antagonism (10 lM): 40 % of GIP(7–30)
Pancreas perfusion: 40% insulin response (10 ng/ml)
CHO cells: IC50 1270 nM [23,38,68]
(17–42) B Pancreas perfusion: 32% insulin response (5 ng/ml) [69]
US RINm5F cells: No cAMP production (1 lM) RINm5F cells: IC50 0.4 lM [23]
(31–44) P L293 cells: No cAMP or pGIP inhibition (10 nM) [62]
C-terminal
(agonists)
(1–6)NH2 US CHO cells: No cAMP production CHO cells: No binding (10 lM) [38]
(1–7)NH2 US CHO cells: No cAMP production CHO cells: No binding (10 lM)
(1–13)NH2 P CHO cells: 13% cAMP (20 lM) CHO cells: 5% binding (10 lM)
(1–14)NH2 P CHO cells: 73% cAMP (20 lM)
26% insulin release (5 nM), sig. glucose decrease
CHO cells: 28% binding (10 lM)
P Pancreas perfusion: No insulin release (10 ng/ml) [68]
(1–14) H CHO cells: Full agonist (cAMP) CHO cells: 51% binding (10 lM) [38]
(1–15)NH2 P CHO cells: 4% cAMP (20 lM) CHO cells: 4% binding (10 lM)
(1–15) P CHO cells: No cAMP production CHO cells: No binding (10 lM)
(1–16) US CHL: 35% cAMP, BRIN-BD11: 10–50% insulin (1 lM) [70]
US BRIN-BD11: Insulin 1.4 fold of basal (1 lM) [71]
(1–30)NH2 R COS cells: Full agonist (cAMP), EC50 equal to GIP COS cells: IC50 0.4nM Figs. 1B and 3B
P CHO and L293 cells: Full agonist (cAMP), EC50 like GIP(1–
42)
RINm5F: cAMP full agonism, 10-fold decreased EC50
Equal glucose decrease (1 pmol/min/100 g)
Pancreas perfusion: Full insulin response (5 nM)
Pancreas perfusion: Full insulin response, 65% reduced
somatostatin response (1 ng/ml)
CHO and L293 cells: IC50 2.0 nM
RINm5F : 10-fold decreased IC50
[38,62,65,72]
US Pancreas: Full insulin response (1 nmol/kg/h)
Stomach: 10-fold lower gastric acid-inhibition
(10 nmol/kg/h)
[41]
(1–30)OH Hu Pancreas perfusion: Full insulin response (1 nM) [65]
(1–38) P Pancreas perfusion: Full insulin response (UC) [73]
(1–39) B Pancreas perfusion: Full insulin response (1 nM) [74]
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Table 2
Overview of truncated GIP variants tested on various GIPR species. The table displays an overview of truncated GIP variants of various different species tested on different species
of GIPR both in vitro and in vivo. Percentages compared to full agonist GIP(1–42) or GIP(1–30) results. Results showing no binding, agonism or antagonism are in italic.
GIP = species sequence of ligand, Hu = human, P = porcine, B = bovine, M = mouse, Ha = hamster, US = unknown species.
Truncation GIP GIPR from other species (human, mouse, porcine, bovine, hamster)




(2–30)NH2 Hu Hu COS cells: 20% efficacy in cAMP, EC50 of 3.7 nM,
Antagonism (1 lM): 50 % inhibition of GIP(1–42)
with EC50 of 22 nM
COS cells: IC50 of 14 nM [27]
(3–30)NH2 Hu Hu COS cells: Antagonism (0.1 lM): 100 % inhibition of
GIP(1–42) with EC50 of 12 nM
COS cells: IC50 of 2.3 nM
(4–30)NH2 Hu Hu COS cells: Antagonism (1 lM): 90 % inhibition of
GIP(1–42) with EC50 of 108 nM
COS cells: IC50 of 22 nM
(5–30)NH2 Hu Hu COS cells: Antagonism (0.1 lM): 85% inhibition of
GIP(1–42) with EC50 of 12 nM
COS cells: IC50 of 5.9 nM
(6–30)NH2 Hu Hu COS cells: Antagonism (0.1 lM): 75% inhibition of
GIP(1–42) with EC50 of 342 nM
COS cells: IC50 of 347 nM
(7–30)NH2 Hu Hu COS cells: Antagonism (0.1 lM): 75% inhibition of
GIP(1–42) with EC50 of 137 nM
COS cells: IC50 of 26 nM
(8–30)NH2 Hu Hu COS cells: No intrinsic cAMP. Antagonism (0.1 lM):
50% inhibition of GIP(1–42) with EC50 of 133 nM
COS cells: IC50 of 79 nM
(9–30)NH2 Hu Hu COS cells: No intrinsic cAMP. Antagonism (0.1 lM):
25% inhibition of GIP(1–42) with EC50 of 450 nM
COS cells: IC50 of 307 nM
(17–30)NH2 US US CHL cells: 1 lM inhibits cAMP (0.1 lM GIP) 15%
BRIN-BD11: 1 lM inhibits insulin (0.1 lM GIP) 11%
[70]
(18–28) Hu P CHO cells: No binding (1 lM) [65]
(19–30)NH2 B Ha Pancreas membranes: No binding [69]




(3–42) Hu Hu COS cells: cAMP, antagonism (1lM): 60 % inhibition
of GIP(1–42) with EC50 of 671 nM
[27]
P Hu COS cells: cAMP, antagonism (1lM): 75 % inhibition
of GIP(1–42) with EC50 of 32 nM
P P Anaesthetized pig: No inhibitory effect on
insulinotropic effects of GIP
[22]
(4–42) B Ha Pancreas membranes: IC50 of
5 nM
[69]
US US CHL cells: 1 lM inhibits cAMP (0.1 lM GIP) 40%
BRIN-BD11: 1 lM inhibits insulin (0.1 lM GIP) 23%
[70]
US M Ob/ob: Glucose increase (25 nmol/kg) [23]
(5–42) US M Ob/ob: Glucose increase (25 nmol/kg)
(7–42) US M Ob/ob: Glucose increase (25 nmol/kg)
(8–42) US M Ob/ob: Glucose increase, sig. insulin decrease
(25 nmol/kg)
(13–42) Hu Hu Titration calorimetry: 6-fold
lower affinity
[43]
(15–42) Hu Hu Titration calorimetry: 10-fold
lower affinity
(17–42) B Ha Pancreas membranes: IC50
0.5 lM
[69]
Hu Hu Titration calorimetry: 15-fold
lower affinity
[43]
(19–42) Hu Hu Titration calorimetry: 17-fold
lower affinity
(21–42) Hu Hu Titration calorimetry: 100-fold
lower affinity
(23–42) Hu Hu Titration calorimetry: No binding
C-terminal
(agonists)
(1–3) B Ha Pancreas membranes: No binding
(10 lM)
[69]
(1–16) B Ha Pancreas membranes: No binding
(10 lM)
US M Ob/ob: No effect on glucose/insulin (25 nmol/kg) [71]
(1–30)NH2 Hu Hu COS cells: Full agonist (cAMP), EC50 equal to
GIP(1–42)
COS cells: IC50 equal to
GIP(1–42)
[27]
(1–30)OH Hu P CHO cells: 11-fold lower affinity
than GIP(1-42)
[65]
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